2 weeks Ago By Defense World Staff
enGene Holdings Inc. ( NASDAQ:ENGN – Get Free Report ) saw a large increase in short interest in the month of September. As of September 15th, there was short interest totalling 216,700 shares, an increase of 38.
7% from the August 31st total of 156,200 shares. Currently, 1.3% of the shares of the company are short sold.
Based on an average trading volume of 123,800 shares, the short-interest ratio is presently 1.8 days. enGene Stock Up 10.
0 % Shares of ENGN stock traded up $0.55 during trading hours on Friday, reaching $6.05.
432,716 shares of the stock were exchanged, compared to its average volume of 99,694. enGene has a 12-month low of $4.42 and a 12-month high of $43.
00. The business’s fifty day moving average is $7.00 and its two-hundred day moving average is $10.
78. The company has a debt-to-equity ratio of 0.09, a current ratio of 19.
52 and a quick ratio of 19.52. The firm has a market capitalization of $267.
20 million, a P/E ratio of -3.52 and a beta of -0.68.
enGene ( NASDAQ:ENGN – Get Free Report ) last announced its quarterly earnings data on Tuesday, September 10th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.
37) by $0.05. As a group, research analysts expect that enGene will post -1.
64 EPS for the current fiscal year. Institutional Investors Weigh In On enGene Wall Street Analysts Forecast Growth A number of equities research analysts have issued reports on ENGN shares. Morgan Stanley reaffirmed an “overweight” rating and set a $40.
00 price objective on shares of enGene in a report on Wednesday, September 11th. Oppenheimer restated an “outperform” rating and issued a $30.00 price target on shares of enGene in a report on Tuesday, September 24th.
Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, enGene currently has an average rating of “Buy” and an average price target of $33.67.
Read Our Latest Analysis on ENGN enGene Company Profile ( Get Free Report ) enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. Further Reading Five stocks we like better than enGene Golden Cross Stocks: Pattern, Examples and Charts Simon Property REIT: A Safe Bet for Growth and Steady Dividends Why Are These Companies Considered Blue Chips? CarMax’s Impressive Rally: What Investors Should Watch Next 2 Fintech Stocks to Buy Now and 1 to Avoid MarketBeat Week in Review – 9/23 – 9/27 Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.
com's FREE daily email newsletter ..
